Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 297,947
  • Shares Outstanding, K 246,237
  • Annual Sales, $ 1,200 K
  • Annual Income, $ -177,120 K
  • EBIT $ -197 M
  • EBITDA $ -195 M
  • 60-Month Beta 1.24
  • Price/Sales 243.37
  • Price/Cash Flow N/A
  • Price/Book 1.22

Options Overview Details

View History
  • Implied Volatility 133.85% ( -29.14%)
  • Historical Volatility 147.39%
  • IV Percentile 84%
  • IV Rank 27.75%
  • IV High 434.72% on 11/13/23
  • IV Low 18.27% on 01/11/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 728
  • Volume Avg (30-Day) 2,357
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 34,877
  • Open Int (30-Day) 31,017

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.17
  • Number of Estimates 4
  • High Estimate -0.16
  • Low Estimate -0.18
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +28.71%
on 11/05/24
2.1750 -40.23%
on 10/18/24
-0.3800 (-22.62%)
since 10/07/24
3-Month
1.0100 +28.71%
on 11/05/24
2.1750 -40.23%
on 10/18/24
-0.2600 (-16.67%)
since 08/07/24
52-Week
0.9200 +41.30%
on 11/10/23
3.7300 -65.15%
on 02/16/24
+0.0500 (+4.00%)
since 11/07/23

Most Recent Stories

More News
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

LXRX : 1.3000 (+7.44%)
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

LXRX : 1.3000 (+7.44%)
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

LXRX : 1.3000 (+7.44%)
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

LXRX : 1.3000 (+7.44%)
Lexicon Announces Outcome of FDA Advisory Committee for Zynquistaâ„¢ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

LXRX : 1.3000 (+7.44%)
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

LXRX : 1.3000 (+7.44%)
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

LXRX : 1.3000 (+7.44%)
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

LXRX : 1.3000 (+7.44%)
VTRS : 13.18 (+13.52%)
Lexicon: Q2 Earnings Snapshot

Lexicon: Q2 Earnings Snapshot

LXRX : 1.3000 (+7.44%)
Lexicon: Q1 Earnings Snapshot

Lexicon: Q1 Earnings Snapshot

LXRX : 1.3000 (+7.44%)

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 1.5433
2nd Resistance Point 1.4467
1st Resistance Point 1.3733
Last Price 1.3000
1st Support Level 1.2033
2nd Support Level 1.1067
3rd Support Level 1.0333

See More

52-Week High 3.7300
Fibonacci 61.8% 2.6566
Fibonacci 50% 2.3250
Fibonacci 38.2% 1.9934
Last Price 1.3000
52-Week Low 0.9200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar